Skip to Content
MilliporeSigma
  • Bacteriological characterization of a Mycobacterium parascrofulaceum strain isolated from a Chinese pneumonia patient.

Bacteriological characterization of a Mycobacterium parascrofulaceum strain isolated from a Chinese pneumonia patient.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2014-05-27)
Guan Liu, Gui-Rong Wang, Xia Yu, Qian Liang, Jing Mu, Yuan-Yuan Shang, Ying Ling, Hai-Qing Zhang, Su-Hua Zheng, Hai-Rong Huang
ABSTRACT

A Mycobacterium parascrofulaceum strain was isolated from a pneumonia patient-the first such reported case from China. The bacteriological characteristics of the strain were determined. Species identification was performed by homologue gene sequence comparison, then a series of biochemical tests was conducted to elucidate the bacteriological characteristics. Drug susceptibility and pathogenicity to mice of the strain were tested. The clinical M. parascrofulaceum strain presented a very similar phenotypic profile to that of Mycobacterium scrofulaceum. The M. parascrofulaceum strain was sensitive to rifabutin, rifapentine, clarithromycin, azithromycin, cefoxitin, and moxifloxacin in vitro. At week 2 post-infection, the lung tissues of mice demonstrated a local inflammatory response denoted by peri-bronchiolar inflammatory infiltrates. At weeks 4 and 8, the lung tissues showed peri-bronchiolar inflammatory infiltrates with large aggregates of lymphocytes and part of the tissue showed granulomatous lesions; there was no appreciable necrosis. The colony-forming units (CFU) count of infected lung and spleen increased gradually during the 8 weeks of the experiment. The M. parascrofulaceum strain isolated in China was sensitive to rifabutin, rifapentine, clarithromycin, azithromycin, cefoxitin, and moxifloxacin. The mycobacteria were capable of proliferating in mice and could lead to pathological changes in the lungs of the mice.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Rifabutin, >98% (HPLC), powder
Sigma-Aldrich
Clarithromycin, ≥95% (HPLC)
Supelco
Clarithromycin, Pharmaceutical Secondary Standard; Certified Reference Material
Azithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Clarithromycin, 96.0-102.0% (HPLC)
USP
Levofloxacin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Rifapentine
Sigma-Aldrich
Ethionamide
USP
Rifabutin, United States Pharmacopeia (USP) Reference Standard
USP
Meropenem, United States Pharmacopeia (USP) Reference Standard
Azithromycin, European Pharmacopoeia (EP) Reference Standard
USP
Azithromycin, United States Pharmacopeia (USP) Reference Standard
Azithromycin for system suitability, European Pharmacopoeia (EP) Reference Standard
USP
Azithromycin Identity, United States Pharmacopeia (USP) Reference Standard
Clarithromycin, European Pharmacopoeia (EP) Reference Standard
Clarithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard
USP
Clarithromycin, United States Pharmacopeia (USP) Reference Standard
Ethionamide, European Pharmacopoeia (EP) Reference Standard
Rifabutin, European Pharmacopoeia (EP) Reference Standard
Supelco
Sulfamethoxazole, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
Ofloxacin, VETRANAL®, analytical standard
Supelco
Ofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Sulfamethoxazole, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Ofloxacin, United States Pharmacopeia (USP) Reference Standard
USP
Clarithromycin Identity, United States Pharmacopeia (USP) Reference Standard
Supelco
Sulfamethoxazole, VETRANAL®, analytical standard
Sigma-Aldrich
4-Aminosalicylic acid, 99%
Sigma-Aldrich
Azithromycin
Sigma-Aldrich
Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)
Sigma-Aldrich
Ofloxacin, fluoroquinolone antibiotic